Galectin Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
02 avr. 2019 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 02, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold...
Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders
06 mars 2019 08h03 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this open letter to...
Galectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Warrants
06 mars 2019 08h02 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today filed a Registration Statement...
Galectin Therapeutics Reports Fiscal 2018 Financial Results and Provides Business Update
06 mars 2019 08h00 HE
|
Galectin Therapeutics Inc.
Planning for Phase 3 clinical trial (NASH-RX) nearing completion for GR-MD-02, the first drug to show positive results in a clinical trial in patients with compensated NASH cirrhosis NORCROSS, Ga.,...
Galectin Therapeutics to Present at Berenberg NASH Day in New York
25 févr. 2019 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H....
Galectin Therapeutics’ Largest Institutional Shareholder Converts Existing Series B Preferred Stock Into Common Stock Streamlining Its Capital Structure
15 janv. 2019 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that its largest...
Galectin Therapeutics Announces Extension of $10 Million Line Credit
20 déc. 2018 08h30 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that its $10 million...
Galectin Therapeutics to Present at the 2nd Annual Anti-Fibrotic Drug Development Summit
19 nov. 2018 09h19 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H....
Galectin Therapeutics to Participate in The ROTH Capital Battle of the NASH Thrones Investment Conference
15 oct. 2018 10h22 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will...
Galectin Therapeutics to Present at The ROTH Capital Battle of the NASH Thrones Investment Conference
15 oct. 2018 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will...